Rationale for triple-combination therapy for management of high blood pressure.
about
Analysis of second- and third-line antihypertensive treatments after initial therapy with an angiotensin II receptor blocker using real-world Japanese data.Single-Pill Combination of Perindopril/Indapamide/Amlodipine in Patients with Uncontrolled Hypertension: A Randomized Controlled Trial.Safety and effectiveness of a fixed-dose combination of olmesartan, amlodipine, and hydrochlorothiazide in clinical practice.Short Term Safety and Tolerability of a Fixed Dose Combination of Olmesartan, Amlodipine and HydrochlorothiazideLeg edema with (S)-amlodipine vs conventional amlodipine given in triple therapy for hypertension: a randomized double blind controlled clinical trial.Three in one: safety, efficacy, and patient acceptability of triple fixed-dose combination medicine in the management of hypertension.Olmesartan/amlodipine/hydrochlorothiazide in participants with hypertension and diabetes, chronic kidney disease, or chronic cardiovascular disease: a subanalysis of the multicenter, randomized, double-blind, parallel-group TRINITY study.Combined olmesartan, amlodipine, and hydrochlorothiazide therapy in randomized patients with hypertension: a subgroup analysis of the TRINITY study by age.Optimizing combination therapy in the management of hypertension: the role of the aliskiren, amlodipine, and hydrochlorothiazide fixed combination.Aliskiren, amlodipine and hydrochlorothiazide triple combination for hypertensionDifferential treatment of hypertension by primary care providers and hypertension specialists in a barber-based intervention trial to control hypertension in Black men.Safety, tolerability, and efficacy of azilsartan medoxomil with or without chlorthalidone during and after 8 months of treatment for hypertensionSingle-pill triple-combination therapy: an alternative to multiple-drug treatment of hypertension.The single pill triple combination of aliskiren, amlodipine, and hydrochlorothiazide in the treatment of hypertension.Hypertension management: rationale for triple therapy based on mechanisms of action.Management of hypertension with fixed-dose triple-combination treatments.Effectiveness of the fixed-dose combination of olmesartan/amlodipine/hydrochlorothiazide for the treatment of hypertension in patients stratified by age, race and diabetes, CKD and chronic CVD.Evaluation of a Pharmacokinetic Interaction between Telmisartan and Chlorthalidone in Healthy Male Adult Subjects.The Antihypertensive Efficacy of the Triple Fixed Combination of Perindopril, Indapamide, and Amlodipine: The Results of the PETRA Study.Triple-combination therapy in the treatment of hypertension: a review of the evidence.Triple Combination Therapies Based on Olmesartan: A Personalized Therapeutic Approach to Improve Blood Pressure Control.Comparison of long-term safety of fixed-dose combinations azilsartan medoxomil/chlorthalidone vs olmesartan medoxomil/hydrochlorothiazide.Incremental effects of antihypertensive drugs: instrumental variable analysis.Single-Center Evaluation of the Pharmacokinetics and Safety of the Angiotensin II Receptor Antagonist Azilsartan Medoxomil in Mild to Moderate Hepatic Impairment.Medication compliance and clinical outcomes of fixed-dose combinations vs free combinations of an angiotensin II receptor blocker and a calcium channel blocker in hypertension treatment.Synergism of amlodipine and candesartan on blood pressure reduction and organ protection in hypertensive rats.Efficacy and safety of sacubitril/valsartan in patients with essential hypertension uncontrolled by olmesartan: A randomized, double-blind, 8-week study.
P2860
Q31117990-A9F104C9-9465-4CEF-B977-E2A85AB5D583Q33734032-95C46BCB-C88F-40CB-B97E-5D5A501202C3Q34764232-51BE6F14-65BD-4D45-96DE-38E111549FD4Q36077409-416BE845-E112-4B88-80AA-69449CEA068EQ36120769-81E60693-3A3E-4657-AF49-1026B117FC33Q36173150-DEB108BD-DFF7-4C4F-B41C-5C0F3D7FE7F7Q36541873-DAD4BAE2-805C-41E2-BC7F-C2BDEE59EDB0Q36941748-0418D2CF-6754-4165-93BE-F3410E036DC5Q36975796-6D8A0082-D84A-4531-87F6-8A96FBBC1619Q37125703-B95FC320-E333-4FD5-85D8-6491B8D24FE8Q37239439-1AB449BA-E941-4E5C-B1BE-1814D213DAF3Q37257463-6AE256FC-4B2B-4E46-B38C-3B6A248263F5Q37959149-9CC3F713-60F5-4485-97B6-86285375730DQ38052172-E93E7354-360C-4EB9-ABF5-AF27AA5422E0Q38057421-DBEBCB98-6E53-4011-B971-288705C2EEB6Q38129014-24A0C62C-4D48-4F57-806C-295FB161A6CFQ38145263-7FA3E525-C9FA-441C-8EB6-1BF2BAADCADCQ38392298-0DC7579B-1543-4954-8DDE-C3E7CE5F3D24Q38711118-FA95BEFA-E8F4-4E0B-AC11-7FD4AAF3AB94Q39147724-A999C17C-8BD8-46E9-B64E-AB30ECB6FD9CQ39368546-B3D9A3E9-3814-4E29-91C9-A9A405A8FC1AQ46669579-F4234365-66F6-4D5F-8DF8-CC2C8E986823Q47256502-6715AF32-14CA-445A-8A34-4C450F884E2AQ48020817-F1A162E5-8E0F-4B5F-8A01-64EF79685219Q48353173-B0CBB891-4401-4A50-A40F-B9AA6F46B6AEQ49380661-77769652-9001-4BA8-B6C6-788393500029Q50026199-930BA310-9783-4210-9FC8-3881222FC95C
P2860
Rationale for triple-combination therapy for management of high blood pressure.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 20 August 2010
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Rationale for triple-combination therapy for management of high blood pressure.
@en
Rationale for triple-combination therapy for management of high blood pressure.
@nl
type
label
Rationale for triple-combination therapy for management of high blood pressure.
@en
Rationale for triple-combination therapy for management of high blood pressure.
@nl
prefLabel
Rationale for triple-combination therapy for management of high blood pressure.
@en
Rationale for triple-combination therapy for management of high blood pressure.
@nl
P2860
P1476
Rationale for triple-combination therapy for management of high blood pressure.
@en
P2093
Alan H Gradman
P2860
P304
P356
10.1111/J.1751-7176.2010.00360.X
P577
2010-08-20T00:00:00Z